The European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) has adopted a set of recommendations on safety signals for medicinal products, following its meeting held from 6 to 9 July 2026. The recommendations, published on 3 August 2026, include directives for marketing authorisation holders (MAHs) to provide supplementary information and, where necessary, to amend product information to reflect new safety concerns. These actions are directly applicable to MAHs for centrally authorised products (CAPs) and nationally authorised products (NAPs), with the latter overseen by national competent authorities (NCAs).
The PRAC's recommendations stem from a review of potential safety signals, which are reports of possible new adverse events or changes in the severity or frequency of known ones. For CAPs, the recommendations have already been endorsed by the Committee for Medicinal Products for Human Use (CHMP) at its plenary meeting on 20-23 July 2026, and the corresponding variations to product information will be assessed by the CHMP. For NAPs, the recommendations are forwarded to the Co-ordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) for information, and it is the responsibility of the NCAs to ensure compliance.
MAHs are reminded of their legal obligation under Article 16(3) of Regulation (EU) 726/2004 and Article 23(3) of Directive 2001/83/EC to keep product information up to date with current scientific knowledge, including PRAC conclusions. The timeline for submitting variations applies to both innovator and generic products, unless otherwise specified. The PRAC may also recommend additional analyses by the Agency or Member States when appropriate.
The publication of these recommendations marks a routine but critical step in the EU's pharmacovigilance system, ensuring that emerging safety information is swiftly incorporated into product labelling and usage guidance. While the specific signals are not detailed in the public summary, the process underscores the ongoing vigilance over medicine safety across the EU, balancing the need for timely regulatory action with the administrative burden on MAHs and national authorities. The recommendations are expected to lead to updates in product information for affected medicines, potentially altering prescribing information and patient leaflets, which could impact healthcare professionals and patients. The EMA's role as the central coordinator ensures consistency across member states, though the actual implementation relies on the cooperation of MAHs and NCAs, highlighting the shared responsibility in maintaining drug safety.